Advanced Oncotherapy (AVO) – Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that between 19 August 2016 and 16 September 2016 Lord David Evans, a Non-Executive Director of the Company, disposed of 136,296 ordinary shares of 25 pence each in the Company (“Ordinary Shares”), at a weighted average price of 121 pence per […]
Advanced Oncotherapy (AVO) – Harley Street planning permission granted
Harley Street planning permission granted Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at a meeting held yesterday at Westminster City Council, planning permission for the Harley Street site was granted. Commenting, Dr. Michael Sinclair, Executive Chairman and CEO of Advanced Oncotherapy, said: “The Harley Street Proton […]
Advanced Oncotherapy (AVO) – Open Offer
Advanced Oncotherapy Open Offer Posting of Circular Further to the announcement made on 30 September 2016, the Company is pleased to announce details of the Open Offer. Introduction The Company announces that up to a maximum of approximately £4.02 million (being below the €5 million threshold which would require the publication by the Company of a […]
Advanced Oncotherapy (AVO) – Directorate Change
Directorate Change As mentioned in the annual report for the year ended 31 December 2015 and in the 2016 notice of Annual General Meeting, Advanced Oncotherapy confirms that Mr Kanoria has stepped down from the board of the Company. Advanced Oncotherapy Plc www.avoplc.com Michael Sinclair, CEO Tel: +44 20 3617 8728 Nicolas Serandour, CFO & […]
Advanced Oncotherapy (AVO) – Subscription & Proposed Open Offer
Subscription & Proposed Open Offer Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces that it has successfully raised £10 million (before expenses) through the issue of 10,000,000 new ordinary shares of 25 pence each (the “New Shares”) in the capital of the Company at a price […]
Advanced Oncotherapy (AVO) – Half-Year Report
Half-Year Report Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2016. The Company continues progressing the technology development of its LIGHT proton therapy system to be used in Harley Street, the first Proton therapy […]
Advanced Oncotherapy (AVO) – Appointment of International Director of Medical Physics
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has appointed Richard Amos as International Director of Medical Physics, a non-board position, with effect from 1 November 2016. Richard joins Advanced Oncotherapy from University College London Hospitals NHS Trust, where he was Operational Lead for Proton Therapy […]
Advanced Oncotherapy (AVO) – Holdings in Company
Advanced Oncotherapy Holding(s) in Company RNS Number : 3207G Advanced Oncotherapy PLC 04 August 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy plc 2 Reason for the notification (please tick the appropriate box or boxes): An […]
Advanced Oncotherapy (AVO) – Holdings in Company
Advanced Oncotherapy Holding(s) in Company RNS Number : 2375G Advanced Oncotherapy PLC 04 August 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An […]
Advanced Oncotherapy (AVO) – Exercise of Warrants, Issue of Shares and Holdings in Company
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 2,000,000 new ordinary shares (“New Shares”) of 25 pence in the Company to PI-Capital LLC, pursuant to the exercise of 2,000,000 warrants at 27.5 pence per New Share. The warrants were issued in 2012. Following […]